Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Piulats

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 4, 2023
Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysisJ M Piulats, C Watkins, M Costa-García, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 18, 2025
Final overall survival and safety analyses of the phase III PSMAfore trial of [<sup>177</sup>Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancerK Fizazi, K N Chi, N D Shore, et al.
Gynecologic Oncology|December 16, 2018
Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patientsV Rodriguez-Freixinos, L Fariñas-Madrid, M Gil-Martin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 10, 2025
Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: a systematic review and meta-analysisS Martín-Lluesma, U Dafni, K Vervita, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 18, 2025
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 studyC Gratzke, M Özgüroğlu, A Peer, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 6, 2017
Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access ProgramM González-Cao, A Arance, J M Piulats, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 20, 2026
Five-Year Survival with Tebentafusp in Metastatic Uveal MelanomaS Piperno-Neumann, P Rutkowski, J C Hassel, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 4, 2023
Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysisJ M Piulats, C Watkins, M Costa-García, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 18, 2025
Final overall survival and safety analyses of the phase III PSMAfore trial of [<sup>177</sup>Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancerK Fizazi, K N Chi, N D Shore, et al.
Gynecologic Oncology|December 16, 2018
Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patientsV Rodriguez-Freixinos, L Fariñas-Madrid, M Gil-Martin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 10, 2025
Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: a systematic review and meta-analysisS Martín-Lluesma, U Dafni, K Vervita, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 18, 2025
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 studyC Gratzke, M Özgüroğlu, A Peer, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 6, 2017
Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access ProgramM González-Cao, A Arance, J M Piulats, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 20, 2026
Five-Year Survival with Tebentafusp in Metastatic Uveal MelanomaS Piperno-Neumann, P Rutkowski, J C Hassel, et al.
Pageof 2